Difficult expression made easy with the EntoEngine™. Utilizing Drosophila melanogaster as our truly continuous expression platform, Future Fields excels in producing difficult to express recombinant proteins, at scale. We leverage parallel multi-cellular screening, multi-strain engineering, inducible expression, and numerous other genetic tools available for d.mel to overcome low expression experienced by traditional manufacturing approaches. Transmembrane proteins, ion channels, GPCRs, nucleases, kinases, and more, make your previously unmake-able protein a reality with Future Fields.